Compare Global E Online Ltd (GLBE) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? Global E Online Ltd trades at $40.37 (market cap $6.75B), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 18.9× Global E Online Ltd's market cap, and Global E Online Ltd is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global E Online Ltd for 21 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| GLBE | VRTX | |
|---|---|---|
Market Cap | $6.75B | $127.55B |
Volume | 1,468,708 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $42.36 | $557.96 |
52-Week Low | $27.54 | $407.37 |
Typical Hold Time | 21 Days | 120 Days |
Enterprise Value | $6.24B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $40.25, up 3.31% today, with a bullish technical signal from moving averages and strong analyst consensus. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth of 39% year-over-year. Recent news includes the appointment of a new Chief Revenue Officer and significant insider selling by executives.
The outlook is positive, supported by strong revenue growth, expanding margins, and a high analyst buy rating. Key risks include elevated valuation multiples, insider selling pressure, and dependence on e-commerce market conditions. The stock offers potential upside to the consensus price target of $48.86.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
